GlassScriptPhysician profile
Neng Lee
NPI 1972511970
$6,347.51
in general payments reported to CMS, 2019-2025
27 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,063 · 2022: $1,319 · 2023: $1,256 · 2024: $1,350 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,923 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.09 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,272.18 | 2021-2025 | Otezla, Repatha, Evenity |
| Gilead Sciences, INC. | $1,208.38 | 2021-2025 | Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $627.13 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $487.98 | 2021-2025 | Airsupra, Farxiga, Tezspire |
| Abbvie INC. | $400.39 | 2021-2025 | |
| Lilly USA, LLC | $368.40 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.83 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $329.48 | 2021-2025 | Wegovy |
| Glaxosmithkline, LLC. | $214.18 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $153.14 | 2022 | |
| Corcept Therapeutics | $125.00 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $113.63 | 2021-2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $91.02 | 2022-2024 | |
| Horizon Therapeutics Plc | $90.34 | 2021-2023 | Krystexxa |
| Abbott Laboratories | $77.68 | 2022-2025 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $72.60 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $65.61 | 2025 | Keveyis, Gvoke Hypopen |
| Mannkind Corporation | $65.38 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $46.04 | 2021 | |
| Amarin Pharma, INC. | $30.93 | 2021 | |
| Insulet Corporation | $27.73 | 2025 | Omnipod |
| Hologic Sales and Service, LLC | $27.42 | 2021 | |
| Alkermes, INC. | $23.75 | 2023 | Aristada, Lybalvi |
| Phathom Pharmaceuticals, INC. | $21.84 | 2024 | Voquezna |
| Pfizer INC. | $21.14 | 2023 | |
| Dexcom, INC. | $19.88 | 2022 | |
| Edwards Lifesciences Corporation | $16.43 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neng Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.